Insider Trading June 30, 2026 04:43 PM

TD SYNNEX Chair Executes $3.98 Million Stock Sale Following Option Exercise

Insider activity occurs as the company reports strong Q2 fiscal 2026 earnings driven by AI infrastructure demand.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
SNX

Dennis Polk, Chair of Hyve Solutions at TD SYNNEX Corp (NASDAQ:SNX), completed a series of stock transactions on June 29, 2026, selling 15,000 shares for approximately $3.98 million. The sales followed the exercise of employee stock options for an equal number of shares. This activity coincides with the company's recent reporting of fiscal second-quarter results that exceeded Wall Street expectations, fueled by accelerating demand in the AI sector.

TD SYNNEX Chair Executes $3.98 Million Stock Sale Following Option Exercise
SNX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • TD SYNNEX Chair Dennis Polk sold 15,000 shares for $3.98 million following the exercise of employee stock options.
  • The company reported Q2 fiscal 2026 earnings of $4.85 per share on $19.6 billion revenue, beating estimates and prompting price target upgrades from UBS and RBC Capital.
  • Growth is attributed to hyperscale infrastructure and enterprise data center modernization, with analysts highlighting accelerating AI demand as a primary catalyst.

Dennis Polk, serving as Chair of Hyve Solutions within TD SYNNEX Corp (NASDAQ:SNX), executed a significant divestment of company equity on June 29, 2026. Polk sold 15,000 shares of common stock, generating a total transaction value of approximately $3.98 million. These sales were directly preceded by the acquisition of an identical quantity of shares through the exercise of employee stock options.

The timing of these transactions occurs against a backdrop of substantial equity appreciation for SNX. Shares have appreciated by more than 101% over the trailing twelve-month period. At the time of the sale, the stock was trading at $267.34. Valuation metrics from InvestingPro analysis suggest the stock remains undervalued relative to its calculated Fair Value, positioning it within the "Most Undervalued stocks" category.

The divestment was structured across multiple transactions with varying execution prices. The weighted average price for the shares sold ranged between $264.75 and $266.37 per share. Individual transaction prices fluctuated within a broader band from $264.39 to $266.60. Specifically, Polk disposed of 3,000 shares at a weighted average of $264.75, 9,533 shares at $265.33, and 2,467 shares at $266.37. These sales were executed as direct holdings.

Earlier on the same date, Polk acquired 15,000 shares by exercising employee stock options at a cost of $107.32 per share, totaling $1,609,800. These options originated from a grant structured to vest 20% upon the first anniversary, with subsequent monthly vesting of 1/60th of the remaining balance. The options carry an expiration date of October 5, 2031.

Following these activities, Polk's direct ownership stands at 22,439 shares of TD SYNNEX common stock. Indirect holdings through a trust amount to 76,647 shares. Additionally, he retains 12,581 employee stock options. For comprehensive valuation and growth analysis, a Pro Research Report is available via InvestingPro.

In related corporate developments, TD Synnex reported fiscal second-quarter 2026 results that surpassed Wall Street consensus. The company posted non-GAAP earnings of $4.85 per share on revenue of $19.6 billion. This performance significantly exceeded analyst estimates of $4.11 per share and $16.79 billion in revenue.

UBS responded to these results by raising its price target for TD Synnex to $352 while maintaining a Buy rating. RBC Capital also increased its price target to $340, citing strong performance driven by accelerating AI demand across Distribution and Hyve segments. Analysts from both firms highlighted the positive impact of hyperscale infrastructure developments and enterprise data center modernization. RBC specifically emphasized the expansion into AI-capable devices as a key driver of the company's robust performance amidst growing technology demands.

Risks

  • The insider sale represents a significant liquidation of equity by a key executive, which may signal valuation concerns despite the company's strong earnings.
  • Heavy reliance on AI infrastructure demand introduces sector-specific volatility risks for the technology distribution and hardware segments.

More from Insider Trading

Disc Medicine's Chief Legal Officer Executes $187,500 Stock Sale Under Pre-Arranged Plan Jun 30, 2026 Ionis Pharmaceuticals EVP Joseph Baroldi’s Spouse Executes Pre-Arranged Stock Sales and Acquisitions Jun 30, 2026 Ionis Pharmaceuticals Executive Offloads Shares Under Pre-Arranged Plan Jun 30, 2026 Ionis Pharmaceuticals Executive Disposes of Shares Under Pre-Arranged Plan Jun 30, 2026 Disc Medicine COO Jonathan Yu Executes $21,750 Stock Sale Under Pre-Arranged Trading Plan Jun 30, 2026